Repotrectinib - Turning Point Therapeutics
At a glance
- Drug Originator TP Therapeutics
- Drug Licenced by ZAI Lab
- Drug Class Antineoplastics; Aza compounds; Fluorobenzenes; Ketones; Macrocyclic compounds; Pyrazoles; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Janus kinase-2 inhibitors; ROS1 protein inhibitors; Src-Family kinase inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
- USA Patent Applicants BRISTOL
- USA Patents 5
- NDAs 1
- International Patents 100

Disclaimer